Related Experiment Video

Updated: May 25, 2026

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

Clofibrate for unconjugated hyperbilirubinemia in neonates: a systematic review

Tao Xiong1, Dapeng Chen, Zhoujin Duan

  • 1Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.

Indian Pediatrics
|February 10, 2012
PubMed

Insights

Clofibrate may reduce the need for and duration of phototherapy in newborns with unconjugated hyperbilirubinemia. Further research is needed to confirm its long-term safety and efficacy.

Area of Science:

  • Neonatal Medicine
  • Pharmacology
  • Evidence-Based Medicine

Background:

  • Unconjugated hyperbilirubinemia is a common condition in newborns.
  • Phototherapy is a standard treatment, but may have limitations.
  • Alternative or adjunctive treatments are being explored.

Purpose of the Study:

  • To systematically review and meta-analyze the efficacy of clofibrate for treating unconjugated hyperbilirubinemia in neonates.
  • To assess the impact of clofibrate on phototherapy requirements and bilirubin levels.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
  • Adherence to Cochrane review group guidelines and PRISMA statement.
  • Inclusion of 13 studies involving 867 infants.

Main Results:

  • Clofibrate administration decreased the need for phototherapy (RR: 0.38) and shortened its duration.
  • Reduced peak total serum bilirubin levels were observed with clofibrate treatment.
  • Benefits were more pronounced in term infants and those without hemolytic diseases.

Conclusions:

  • Clofibrate shows potential short-term benefits for neonatal hyperbilirubinemia, particularly in specific infant populations.
  • Further large-scale RCTs with long-term follow-up are necessary to establish safety and long-term effects.
  • The study did not provide data on mortality or kernicterus.
Abstract

More Related Videos

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children07:27

How to Administer Near-Infrared Spectroscopy in Critically ill Neonates, Infants, and Children

Published on: August 19, 2020

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...